Company Performance Metrics
Fosca Biotech is a French oncology startup developing a first-in-class medical device that filters the tumor microenvironment (TME) — offering a disruptive, non-pharmaceutical alternative to traditional cancer treatment. Unlike chemotherapy or immunotherapy, Fosca’s approach focuses on physically detoxifying the cancerous environment to improve
immune access, reduce metastasis, and lower systemic toxicity.
Rooted in cutting-edge microfluidics and deep immunological insight, Fosca’s innovation targets a well-documented barrier in oncology: the hostile TME that protects tumors and blocks therapy. By filtering it over long periods via the use of a unique and proprietary medical device, Fosca aims to reestablish natural immunity, enabling more effective and less harmful treatment options.
Fosca is currently raising €2M in seed funding to support preclinical development, regulatory planning, and strategic partnerships. The founding team combines expertise in oncology, device engineering, and medtech commercialization.
